# AmerisourceBergen Corporation – Consensus ‘buy’ rating and 16.2% Upside Potential - Link: https://www.directorstalkinterviews.com/amerisourcebergen-corporation-consensus-buy-rating-and-16.2-upside-potential-3/4121126740 - Published: 2023-09-07T12:49:36+01:00 - Author: Charlotte Edwards **AmerisourceBergen Corporation** which can be found using ticker (ABC) now have 14 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between 225 and 190 suggesting an average Analsyt target price of $209.57. Given that the stocks previous close was at $180.39 and the analysts are correct then there would likely be a percentage uptick in value of 16.2%. There is a 50 day moving average of $186.14 and the 200 moving average now moves to $171.03. The total market capitalization for the company now stands at 36.15B. The current share price for the company is: 179.98 USD The potential market cap would be $41,997,301,323 based on the market consensus. The company has a dividend yield of 1.09%. Other points of data to note are a P/ E ratio of 21.92, revenue per share of 1247.29 and a 2.7% return on assets. AmerisourceBergen Corporation is a global pharmaceutical sourcing and distribution services company. The Company’s U.S. Healthcare Solutions segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the- counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. This segment consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty. The Company also focuses on specialty services and a global platform of pharma manufacturer services capabilities. Share on: